A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients.
about
Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infectionsRandomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infectionWhat preclinical data are needed to justify once-daily therapy?Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.Mezlocillin for treatment of infections in cancer patientsDoes prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials.Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.Role of pharmacokinetics and pharmacodynamics: does the dose matter?What do we really know about antibiotic pharmacodynamics?Continuous infusion of piperacillin/tazobactam in septic critically ill patients--a multicenter propensity matched analysis.Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infectionsIn vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patientsPharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers.Influence of four modes of administration on penetration of aztreonam, cefuroxime, and ampicillin into interstitial fluid and fibrin clots and on in vivo efficacy against Haemophilus influenzae.A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients.Imipenem-cilastatin as initial therapy for febrile cancer patientsContinuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats.Continuous infusion of beta-lactam antibioticsRandomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients.Continuous beta-lactam infusion in critically ill patients: the clinical evidenceInfluence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection.Pharmacodynamics of antimicrobials: treatment optimisation.Pharmacodynamic optimization of beta-lactams in the patient care setting.An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Measurement of piperacillin plasma concentrations in cancer patients with suspected infection.Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.Role of pharmacokinetics in the outcome of infections.Piperacillin plus vancomycin in the therapy of febrile episodes in cancer patientsExtended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia.Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.Beta-lactam antibiotics: is continuous infusion the preferred method of administration?Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.Pharmacoeconomic evaluation of once-daily aminoglycoside treatment.Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?Combinations of beta lactam antibiotics.Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
P2860
Q24199096-20F4555F-3DB4-4C64-A948-1E52870CA645Q24675002-80AE94D1-B9F1-4FC1-BB83-23A2278A860BQ30899947-A145A795-35F9-4899-8076-8E4918F8ACADQ33695281-0210394F-1460-4700-8E43-51C40928CA81Q33730391-EDB3F06F-563C-4080-8312-E32E49839D55Q33940174-9214CD76-8711-4884-B964-52596E14B43BQ33981666-4E77AD0E-C60F-4F16-B884-236B0A1F19B4Q34347932-E21B4B66-B2F1-434A-AF3C-37689FCEFBC5Q34443407-72BE3C4E-95CC-4341-942B-2FD817912BADQ34490565-38ABF5B5-95DD-4B27-A74E-1C990FFCF927Q35117352-E2981809-24C7-44C1-85F2-C1A93986C1D1Q35121441-40AB6B36-5822-46B2-9475-861C73F40E6EQ35123123-BF488C7C-8E40-4999-9B1F-5825B23CF243Q35138316-211D9716-AA8C-40ED-AD8A-22BD0F557B1CQ35284383-F7B1E2CF-4FB0-4AE8-B9D5-8B68888D1238Q35646823-AC15EF5E-E781-45CC-AF83-F83BE226D926Q35648068-8C3074F9-2567-46A1-838B-4D2AB6096C52Q35651131-0A52C88B-46E1-49D0-B146-D43F96F002C9Q35652730-9665EB67-D17D-4924-B743-9E0DD71ED96EQ35656806-44FA6A89-BE73-4DDF-A121-677E4D8E650EQ35817652-31ECDD0D-F2EB-40A9-AB37-7FFB791ECB15Q36329228-5B5F177F-E9C7-4B9E-B783-D0E9149B41ECQ36505518-669370B5-AA45-4398-9FCF-2FEB9B06EC99Q36544935-ADD9283F-E428-4BD6-BBA3-F2460A9BE29CQ37169843-C127F01F-B134-43EB-B557-FE93B41EC39BQ37563029-96630B3B-D6B1-4248-978F-5DD9BF2C7E8EQ38779422-7BA6F9E9-D8D1-468F-A1E6-A8800FAC12CBQ38896040-8A60874C-ECF4-4BFD-B1FE-AF4367C7AD40Q39639407-45C1BC58-66A2-4417-B404-0CD99BF987ACQ39833436-34D244FE-0547-44DA-A84B-D40CC0A32CC2Q40073466-42C3D39E-A49A-4DF2-A2D7-EECAED8B6C9AQ40087256-206A5352-19C4-40FF-94D1-B0FA29394259Q40459002-DCB3F00C-51CD-40A9-B532-1EB6894E1B58Q40585005-3E7725F9-A9F7-4307-9CF8-27BD6D40DF29Q40949900-0907AF43-B2AA-486A-A51C-89E04FFE3ADAQ42432137-E7E931C5-7F61-4355-8749-95D2188C215EQ43048864-B95A3EEF-C69A-4674-89F9-3661D723D2C1Q44551301-7EF20EBA-84E8-4E21-AF5A-51F1B97DBA09Q44601141-D7D38837-C9FE-4D72-8A33-C9819EB17CCBQ44740259-58766CE2-FB73-467B-9271-8C85750E9F4E
P2860
A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients.
description
1979 nî lūn-bûn
@nan
1979年の論文
@ja
1979年論文
@yue
1979年論文
@zh-hant
1979年論文
@zh-hk
1979年論文
@zh-mo
1979年論文
@zh-tw
1979年论文
@wuu
1979年论文
@zh
1979年论文
@zh-cn
name
A randomized study of carbenic ...... e episodes in cancer patients.
@en
type
label
A randomized study of carbenic ...... e episodes in cancer patients.
@en
prefLabel
A randomized study of carbenic ...... e episodes in cancer patients.
@en
P2093
P1476
A randomized study of carbenic ...... e episodes in cancer patients.
@en
P2093
P304
P356
10.1016/0002-9343(79)90242-0
P407
P577
1979-10-01T00:00:00Z